Shares Magazine
11.00p+0.00 (+0.00%)24 Dec 2024, 09:13
Jump to:
Rua Life Sciences PLC Fundamentals
| Company Name | Rua Life Sciences PLC | Last Updated | 2024-12-24 |
|---|---|---|---|
| Industry | Medical Devices | Sector | Healthcare |
| Shares in Issue | 62.060 m | Market Cap | £6.83 m |
| PE Ratio | 8.53 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.04 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.1199 | Debt Equity Ratio | 0.0974 |
| Asset Equity Ratio | 1.2279 | Cash Equity Ratio | 0.4732 |
| Quick Ratio | 5.0460 | Current Ratio | 6.47 |
| Price To Book Value | 0.8682 | ROCE | 0 |
Rua Life Sciences PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Rua Life Sciences PLC Company Financials
| Assets | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tangible Assets | £2.46 m | £2.74 m | £2.60 m | £1.95 m |
| Intangible Assets | £720,000.00 | £771,000.00 | £822,000.00 | £875,000.00 |
| Investments | 0 | 0 | 0 | 0 |
| Total Fixed Assets | £3.18 m | £3.51 m | £3.42 m | £2.83 m |
| Stocks | £112,000.00 | £81,000.00 | £124,000.00 | £85,000.00 |
| Debtors | £532,000.00 | £422,000.00 | £915,000.00 | £862,000.00 |
| Cash & Equivalents | £3.93 m | £1.48 m | £2.96 m | £6.29 m |
| Other Assets | 0 | 0 | 0 | 0 |
| Total Assets | £8.17 m | £5.66 m | £7.63 m | £10.15 m |
| Liabilities | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Creditors within 1 year | £554,000.00 | £414,000.00 | £511,000.00 | £1.10 m |
| Creditors after 1 year | £433,000.00 | £566,000.00 | £531,000.00 | £550,000.00 |
| Other Liabilities | 0 | 0 | 0 | 0 |
| Total Liabilities | £987,000.00 | £980,000.00 | £1.04 m | £1.65 m |
| Net assets | £7.18 m | £4.68 m | £6.58 m | £8.51 m |
| Equity | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Called up share capital | £3.10 m | £1.11 m | £1.11 m | £12.95 m |
| Share Premium | £25.55 m | £23.57 m | £23.57 m | £11.73 m |
| Profit / Loss | -£2.02 m | -£2.32 m | -£2.36 m | -£1.59 m |
| Other Equity | £7.18 m | £4.68 m | £6.58 m | £8.51 m |
| Preference & Minorities | 0 | 0 | 0 | 0 |
| Total Capital Employed | £7.18 m | £4.68 m | £6.58 m | £8.51 m |
| Ratios | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Debt Ratio | £0.04 | £0.07 | £0.04 | £0.04 |
| Debt-to-Equity | £0.04 | £0.08 | £0.04 | £0.04 |
| Assets / Equity | 1.2279 | 1.2279 | 1.2279 | 1.2279 |
| Cash / Equity | 0.4732 | 0.4732 | 0.4732 | 0.4732 |
| EPS | -£0.04 | -£0.09 | -£0.09 | -£0.08 |
| Cash Flow | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cash from operating activities | -£1.33 m | -£1.15 m | -£2.35 m | -£1.41 m |
| Cashflow before financing | £2.56 m | -£1.01 m | -£2.42 m | £5.27 m |
| Increase in Cash | £2.48 m | -£1.49 m | -£3.33 m | £4.32 m |
| Income | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Turnover | £2.19 m | £2.18 m | £1.63 m | £1.53 m |
| Cost of sales | £415,000.00 | £388,000.00 | £267,000.00 | £276,000.00 |
| Gross Profit | £1.78 m | £1.79 m | £1.36 m | £1.25 m |
| Operating Profit | -£1.94 m | -£2.31 m | -£2.35 m | -£1.55 m |
| Pre-Tax profit | -£2.02 m | -£2.32 m | -£2.36 m | -£1.59 m |
Rua Life Sciences PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives the majority of its revenue from the USA and has a presence in Switzerland, Italy, the UK, and Israel. |
| Latest Interim Date | 11 Dec 2024 |
| Latest Fiscal Year End Date | 24 Jul 2024 |
Rua Life Sciences PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2020-12-11 | Mr. James Gordon Wright | Non-Executive Director |
| 2013-12-03 | Mr. Francis Patrick Maguire | Executive Director,Chief Executive |
| 2012-12-31 | Mr. Jonathan Peter Pither | Non-Executive Director |
| 2024-07-26 | Mr. Ian Leslie Ardill | Non-Executive Director |
| 2016-10-31 | Mr. Edward Eddie McDaid | Executive Director,Chief Executive Officer |
| 2024-07-26 | Mr. William Donald Brown | Executive Director,Chief Executive Officer |
| 2011-10-21 | Dr. Stuart Bernard Rollason | Non-Executive Director |
| 2015-06-01 | Mr. Roy Walter Mitchell | Non-Executive Director,Finance Director |
| 2024-07-26 | Mr. John McKenna | Executive Director,Director of Clinical Marketing |
| 2024-07-26 | Mr. John Louis Ely | Non-Executive Director |
| 2024-07-26 | Mr. Geoffrey Alan Berg | Non-Executive Director,Chairman |
| 2021-08-10 | Mr. David Muir Richmond | Executive Director,Chief Executive Officer |
| 2024-07-26 | Dr. Caroline Stretton | Executive Director,Managing Director |
| 2024-07-26 | Mr. Lachlan Arthur Smith | Executive Director,Company Secretary and Group Chief Financial Officer |
| 2024-07-26 | Dr. Iain Crawford Anthony | Executive Director,Director of Clinical and Regulatory Affairs |
Rua Life Sciences PLC Contact Details
| Company Name | RUA Life Sciences PLC |
|---|---|
| Address | c/o Kergan Stewart LLP, 163 Bath Street, Glasgow, G2 4SQ |
| Telephone | |
| Website | https://www.rualifesciences.com |
Rua Life Sciences PLC Advisors
| Registrar | Equiniti Limited |
|---|
| Stockbroker | FinnCap |
|---|---|
| Phone | +44 2072200500 |
| Fax | +44 2076001659 |
| Auditor | Grant Thornton UK LLP |
|---|---|
| Phone | (0116) 247 1234 |
| Fax | (0116) 247 1434 |
| Solicitor | DAC Beachcroft LLP |
|---|---|
| Phone | +44 2072421011 |
| Fax | +44 2078316630 |
| Solicitor | Brodies LLP |
|---|---|
| Phone | (0131) 228 3777 |
| Fax | (0131) 228 3878 |
| Bank | Bank of Scotland |
|---|
| Nominated Adviser | FinnCap |
|---|---|
| Phone | +44 2072200500 |
| Fax | +44 2076001659 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| North Atlantic Smaller Companies Investment Trust PLC | 3,770.00 | 4.72 |
| Harworth Group PLC | 176.50 | 4.44 |
| Mobico Group PLC | 79.85 | 4.17 |
| Ithaca Energy PLC | 107.00 | 3.88 |
| Airtel Africa PLC | 112.80 | 3.87 |
| Bakkavor Group PLC | 149.50 | 3.82 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Vistry Group PLC | 547.50 | -16.28 |
| Persimmon PLC | 1,182.00 | -2.39 |
| Entain PLC | 681.40 | -1.25 |
| Firstgroup PLC | 164.40 | -1.20 |
| Jpmorgan Japanese Investment Trust PLC | 555.00 | -1.07 |
| Puretech Health PLC | 154.80 | -1.02 |
Risers/fallers data from previous trading day.